Drugs / CpG-STAT3 siRNA CAS3/SS3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04995536 | Jul 2021 → Jan 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma | City of Hope Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CpG-STAT3 siRNA CAS3/SS3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04995536 ↗ |
| Modality | Small interfering RNA (siRNA) | “This investigational drug combines a CpG oligonucleotide and an siRNA in one molecule” NCT04995536 ↗ |
| Route | Other | “Given intratumorally” NCT04995536 ↗ |
| Target | STAT3 | “CAS3/SS3 simultaneously targets two molecules, TLR9 receptor and STAT3.” NCT04995536 ↗ |
| Target | TLR9 | “CAS3/SS3 simultaneously targets two molecules, TLR9 receptor and STAT3.” NCT04995536 ↗ |